Breast mass
Methodology & AI Transparency ⓘ
Breast mass Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Breast mass (N63.0; Prostate (BPH), Bladder & Urinary Tract) utilize urinalysis/urine culture [Breast mass N63.0] and objective Urinalysis & Post-Void in Breast mass (N63.0: Residual (PVR)) targets (Negative leukocyte/nitrite; PVR < 50 mL (N63.0)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Mapped to Prostate (BPH), Bladder & Urinary Tract under ICD-10-CM N63.0 for Breast mass clinical workups.
- 3 Typical cash cost range: Primary evaluation for Breast mass incorporates urinalysis/urine culture [Breast mass N63.0] and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Breast mass: Urinalysis & Post-Void in Breast mass (N63.0: Residual (PVR)) (Negative leukocyte/nitrite; PVR < 50 mL (N63.0)) and Total PSA & in Breast mass (N63.0: Serum Creatinine/eGFR).
Ask our AI Specialists anything about Breast mass
What Is Breast mass?
Physicians managing Breast mass (N63.0; Prostate (BPH), Bladder & Urinary Tract) utilize urinalysis/urine culture [Breast mass N63.0] and objective Urinalysis & Post-Void in Breast mass (N63.0: Residual (PVR)) targets (Negative leukocyte/nitrite; PVR < 50 mL (N63.0)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in urology & prostate, Breast mass (N63.0) involves or detrusor overactivity [Breast mass N63.0]. progression correlates with shifts in Urinalysis & Post-Void in Breast mass (N63.0: Residual (PVR)) (Negative leukocyte/nitrite; PVR < 50 mL (N63.0)).
Common Symptoms & Clinical Signs
- • Presentation of Breast mass (N63.0): burning dysuria, suprapubic in Breast mass (N63.0: discomfort, or cloudy/hematuric)
- • Secondary Breast mass clinical sign: sudden severe flank-to-groin in Breast mass (N63.0: colicky pain caused)
- • Symptom flares in Breast mass correlating with Urinalysis & Post-Void in Breast mass (N63.0: Residual (PVR)) deviation outside Negative leukocyte/nitrite; PVR < 50 mL (N63.0)
- • Functional urology & prostate impact requiring urinalysis/urine culture [Breast mass N63.0] evaluation (N63.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Breast mass Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N63.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Prostate (BPH), Bladder & Urinary Tract | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Urinalysis & Post-Void in Breast mass (N63.0: Residual (PVR)) | Negative leukocyte/nitrite; PVR < 50 mL (N63.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Total PSA & in Breast mass (N63.0: Serum Creatinine/eGFR) | Age-specific PSA; eGFR > 75 mL/min (N63.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: IPSS Urinary Symptom in Breast mass (N63.0: Score) | 0 – 7 (mild symptoms) (N63.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Breast mass
Treatment selection for Breast mass depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Breast mass)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Effect of concomitant statin treatment in postmenopausal patients with hormone: What a 3,420-Participant Study Found According to this analysis, hydrophilic statins showed a detrimental effect on DFS in the main model, which was attenuated after correction for confounders. ESMO open • 2022-04-15 • Phase III Randomized Trial | N = 3,420 | 96/100 | PMID 35334418 ↗ |
| New Insights on TQB2440 compared with reference pertuzumab for HER2-positive, ER/PgR-negative,: What a 412-Participant Study Found TQB2440 showed equivalent efficacy, comparable safety, PK, and immunogenicity profiles to reference pertuzumab in the neoadjuvant treatment of patients with HER2-positive early or locally advanced breast cancer. ESMO open • 2026-01-15 • Phase III Randomized Trial | N = 412 | 93/100 | PMID 41401771 ↗ |
| New Insights on Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or: What a 275-Participant Study Found These findings support lerociclib plus fulvestrant as a treatment option for patients with HR+/HER2- endocrine-resistant advanced breast cancer (ABC). Nature communications • 2025-01-16 • Phase III Randomized Trial | N = 275 | 93/100 | PMID 39820749 ↗ |
| New Insights on Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer: What a 509-Participant Study Found Final OS data indicate that the PFS improvement shown in the primary analysis did not translate into an OS benefit. European journal of cancer (Oxford, England : 1990) • 2024-03-15 • Phase III Randomized Trial | N = 509 | 93/100 | PMID 38309017 ↗ |
| Can This Approach Help? Inside the Latest Research on 5-year outcomes of chemotherapy de-escalation in HER2-positive early breast Nature Medicine, Published online: 29 October 2026; doi:10.1038/s41591-026-04723-w A 5-year secondary analysis of the phase 2 PHERGain trial supports the clinical utility of a PET-guided adaptive strategy for treatment de-escalation in HER2-positive early brea Nature Medicine • 2026-10-29 • Peer-Reviewed Journal (Longevity & Biotech) | Multi-cohort | 92/100 | PMID NATURE_MED-4248748391 ↗ |
Breast mass Patient Community & “People Like Me” Threads
Filter Breast mass community threads and patient logs by age, biological sex, dosage, and treatment duration.